Dry Powder Inhaler Market

Dry Powder Inhaler Market Analysis, By Product Type (Capsule-based Devices, Blister-based Devices, Reservoir/Cartridge-based Devices), By Application (Bronchitis, Chronic Obstructive Pulmonary Diseases (COPD), Asthma), By Sales Channel (Offline, Online) & By Region - Global Market Insights 2021 to 2031

Analysis of Dry Powder Inhaler market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more

Dry Powder Inhaler Market Outlook (2021-2031)

The global dry powder inhaler market is expected to top US$ 1.3 Bn by 2031, rising at a CAGR of 7.2% through 2021-2031. The market is estimated to create an absolute $ opportunity of about US$ 458 Mn by 2031. Currently, dry powder inhaler sales account for more than 35% of the global inhaler market.

Dry Powder Inhaler Market Size (2020A) US$ 813.6 Mn
Projected Year Value (2031F) US$ 1.3 Bn
Value CAGR (2021-2031) 7.2%
Collective Value Share (U.S., U.K., Germany): Top 3 Countries 44.6%
Key Companies Profiled
  • AstraZeneca
  • GlaxoSmithKline plc
  • Vectura Group plc
  • Boehringer Ingelheim GmbH
  • Otsuka Pharmaceutical Co. Ltd.
  • Norton Healthcare
  • Respira Therapeutics, Inc.
  • Cheisi
  • Cipla
  • Hovione
  • 3M
  • OPKO
  • Teva


Dry Powder Inhaler Sales Analysis (2016-2020) Vs Market Outlook (2021-2031)

Owing to rise in occurrence of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), emphysema, and bronchitis, the dry powder inhaler device industry is expected to experience robust growth.

Rising respiratory disorders such as asthma and chronic obstructive pulmonary diseases, surge in per capita healthcare spending, and increased air pollution levels, especially in emerging countries, are major factors contributing to increase in consumption of dry powder inhalers (DPI) across the globel.

Fact.MR projects the market to remain steady, exhibiting growth at 7.2% CAGR from 2021 and 2031 in comparison to the CAGR of 5.8% posted from 2016 to 2020.

Basically, DPI helps the medicine to get deep into the lungs, which is beneficial for asthma treatment for kids and teens. These inhalers hold the medicine as a dry powder, unlike other inhalers that deliver a puff of medicine. Users have to breathe in fast and deep to get the medicine into the lungs, as the medicine sits inside as a powder.

One of the major benefits of dry powder inhalers is that they are used for the treatment of an increasingly diverse range of diseases. However, the engineering development of this medical technology is proving to be a great challenge, as drug delivery from a DPI involves a complex interaction between the device and the patient.

Know thy Competitors

Competitive landscape highlights only certain players
Complete list available upon request

Competition among Manufacturers Restricting New Entrants into the Market

Key players in the dry inhaler market are gradually shifting their focus towards strengthening retail as a distribution channel and working out effective marketing strategies. Escalating breathing problems such as asthma coupled with rising geriatric population in North America have resulted in increased usage dry powder inhaler systems.

Market entry is not easy in this highly competitive space. Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by market participants.

  • For instance, rights for the development and commercialization of an innovative multi-use blister-based, and ultra-affordable dry powder inhaler device (Papillon DPI), was acquired by Hovione Technology, and was patented by Dr. Klaus-Dieter Beller.

Dry powder inhaler market by product type by Fact.MR

Country-wise Insights

What is the Market Scenario of Dry Powder Inhalers in the U.S.?

The North American market for dry powder inhalers is anticipated to depict the largest share of sales across the globe, currently dominating with a market share of 35.7%. This can be attributed to the presence of well-established healthcare infrastructure, key market players, as well the constantly investing into research and development activities.

Moreover, growing prevalence of asthma and other respiratory diseases coupled with rising geriatric population, the U.S. dry powder inhaler devices market growth is said to be prominent over the decade.

What’s Driving the Asia Pacific Dry Powder Inhaler Market?

Asia Pacific is predicted to be a significant-growing market for the sales of dry powder inhaler devices during the assessment period of 2021-2031. This is due to rising expenses on healthcare followed by rapidly enhancing medical infrastructure in countries such as China and India, which is anticipated to propel market growth over the coming years.

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

Category-wise Insights

Which Type of Dry Powder Inhalers are Most Used in the Industry?

Capsule-based devices are expected to dominate the global dry powder inhaler formulation market during the forecast period, owing to increase in the number of manufacturers offering diverse products in the segment and rise in the adoption and preference of healthcare providers and patients for these devices.

Why are Hospital Pharmacies Proliferating from the Sales of Dry Powder Inhalers?

On the basis of distribution channel, hospital pharmacies acquired the largest market share for the sales of dry powder inhalers in 2020. Owing to the consistent increase in the number of hospital pharmacies in countries such as Brazil, India, and China, and rising number of prescriptions for dry powder inhalers by hospitals, a positive impact on market growth is expected for the forecast period.

Offline sales channels hold a higher (94.9%) market share than online channels (5.1%) in the dry powder inhaler market. But online channels are expected to grow at a higher rate as compared to offline channels in the dry powder inhaler market over the forecasted period.

Impact of COVID-19

A huge impact of the pandemic has been seen across different industries in the world. This impact has shaken the economy and caused a disturbance in the equilibrium.

The spread of coronavirus has been proved lethal for many across the globe. This pandemic has given way to several breathing concerns and respiratory issues that are more harmful for people already suffering from asthma, which is expected to increase demand for dry powder inhalers.

Also, breathlessness or shortness of breath is a common symptom among patients infected with COVID-19. This is likely to contribute to increasing sales of dry powder inhalers over the coming months and years.

Competitive Landscape

The global market for dry powder inhaling devices is a fragmented one, imputing to the existence of many domestic and regional players. Mergers, expansion, acquisitions, and partnerships of companies, along with new product development as strategic approaches are being adopted by leading companies to upscale their market presence and create a large customer base.

  • For instance, Lonza, a chemicals and biotechnology solutions firm, lately launched a Center of Excellence for Dry Powder Inhaler (DPI) drug product development at its existing site in Bend, OR, where the company will use its expertise in particle engineering to help customers create and evaluate formulations.

Key Segments Covered in Dry Powder Inhaler Industry Research

  • By Product Type

    • Capsule-based Devices
    • Blister-based Devices
    • Reservoir/Cartridge-based Devices
    • Others
  • By Application

    • Bronchitis
    • Chronic Obstructive Pulmonary Diseases (COPD)
    • Asthma
    • Others
  • By Sales Channel

    • Offline Channels
    • Hospital Pharmacies
    • Retail Pharmacies
    • Drug Stores
    • Other Sales Channels
    • Online Channels
  • By Region

    • North America Dry Powder Inhaler Market
    • Latin America Dry Powder Inhaler Market
    • Europe Dry Powder Inhaler Market
    • South Asia Dry Powder Inhaler Market
    • East Asia Dry Powder Inhaler Market
    • Oceania Dry Powder Inhaler Market
    • Middle East Africa Dry Powder Inhaler Market

- FAQs -

The global dry powder inhaler market is worth around US$ 857 Mn at present.

Dry powder inhaler sales are anticipated to surpass US$ 1.3 Bn by 2031-end.

Global demand for dry powder inhalers rose at a CAGR of 5.8% from 2016 to 2020.

AstraZeneca, GlaxoSmithKline plc, Vectura Group plc, Boehringer Ingelheim GmbH, Otsuka Pharmaceutical Co. Ltd., Norton Healthcare, and Respira Therapeutics, Inc. are prominent dry powder inhaler suppliers.

The U.S., U.K., Germany, China, and India are countries contributing to high demand for dry powder inhalers.

The U.S. dry powder inhaler market share in 2021 is around 89.1% of the North American market, and the Australian market size in 2021 is around 65.7% of the overall Oceania market.

Dry Powder Inhaler Market

Schedule a Call

We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic.

By clicking "Accept All", you consent to our use of cookies. Privacy Policy